Abstract
This document, produced with the assistance of GPT-5.2 Thinking and Gemini 3 Raisonnement, is released under the Apache License 2.0. It is a voluntary defensive publication (prior art) and therefore enters the prior art upon release under the applicable patent statutes : EPC Art. 54(2) (European Patent Convention), French IPC Art. L 611-11 (French Intellectual Property Code), 35 U.S.C. §102(a) (United States Patent Act), Chinese Patent Law Art. 22(5) (中华人民共和国专利法), and Japanese Patent Act Art. 29(1) (特許法). It discloses enabling innovations around Ir@C60: arc/laser synthesis, HPLC purification and density-gradient pre-enrichment, QA/QC standards, IV/oral formulations, regenerative biomaterials, bioelectronic sensors, CT imaging and AI reconstruction, closed-loop dosing protocols, cloud/federated safety analytics, and supply chain/packaging engineering, in order to pre-empt future patent claims.
Original Zenodo url: https://zenodo.org/records/18116725
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Pillet, Xavier, "Strategic report: Ir@C60 in regenerative medicine and longevity", Technical Disclosure Commons, (January 02, 2026)
https://www.tdcommons.org/dpubs_series/9116